AI Engines For more Details: Perplexity Kagi Labs You
Contraception: Norethindrone is commonly used in combination with estrogen in oral contraceptive pills (birth control pills) to prevent pregnancy. It works by inhibiting ovulation (the release of an egg from the ovary), thickening cervical mucus to impede sperm penetration, and altering the uterine lining to prevent implantation of a fertilized egg. Norethindrone-only pills (progestin-only pills or minipills) are also available and primarily work by thickening cervical mucus and altering the uterine lining.
Menstrual Disorders: Norethindrone-containing contraceptive pills may be prescribed to regulate menstrual cycles and treat menstrual disorders such as irregular or heavy menstrual bleeding (menorrhagia). By stabilizing hormonal fluctuations, norethindrone can help promote regular and lighter menstrual periods. Progestin-only pills may also be used to manage menstrual irregularities.
Hormone Replacement Therapy (HRT): Norethindrone, often in combination with estrogen, is used in hormone replacement therapy for postmenopausal women to alleviate symptoms of menopause, such as hot flashes, vaginal dryness, and mood changes. It can help replace the hormones that the body stops producing after menopause, thereby reducing symptoms and preventing bone loss.
Endometriosis: Norethindrone may be prescribed to treat endometriosis, a condition in which tissue similar to the lining of the uterus grows outside the uterus, causing pain and other symptoms. By suppressing ovulation and thinning the uterine lining, norethindrone can help alleviate symptoms associated with endometriosis, such as pelvic pain and heavy menstrual bleeding.
Polycystic Ovary Syndrome (PCOS): Norethindrone may be used to regulate menstrual cycles and reduce androgen levels in women with polycystic ovary syndrome (PCOS), a hormonal disorder characterized by irregular periods, excess hair growth, and ovarian cysts. By inhibiting ovulation and lowering androgen levels, norethindrone can help improve symptoms of PCOS.
Breast Cancer: In some cases, norethindrone may be used as part of the treatment for advanced breast cancer, particularly in postmenopausal women. It may help slow the growth of hormone receptor-positive breast cancer cells by blocking estrogen production in the body.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
Acne | 0 | 0 | |
ADHD | 0.6 | 0.6 | |
Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
Allergic Rhinitis (Hay Fever) | 0.5 | 0 | 0 |
Allergies | 0.5 | 0.4 | 0.25 |
Allergy to milk products | 0.8 | 0.4 | 1 |
Alopecia (Hair Loss) | 0.4 | 0.4 | |
Alzheimer's disease | 1.1 | 1.7 | -0.55 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.7 | 0.57 |
Ankylosing spondylitis | 1.3 | 0.8 | 0.63 |
Anorexia Nervosa | 0.2 | 0.7 | -2.5 |
Antiphospholipid syndrome (APS) | 0.5 | 0.4 | 0.25 |
Asthma | 0 | 0.1 | 0 |
Atherosclerosis | 0.3 | 0.3 | |
Atrial fibrillation | 1.1 | 0.9 | 0.22 |
Autism | 1 | 2.5 | -1.5 |
Barrett esophagus cancer | 0.2 | 0.2 | |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 1.1 | 0.4 | 1.75 |
Brain Trauma | 0 | 0.1 | 0 |
Carcinoma | 1.1 | 0.5 | 1.2 |
Celiac Disease | 0.7 | 1.5 | -1.14 |
Cerebral Palsy | 0.2 | 0.3 | -0.5 |
Chronic Fatigue Syndrome | 0.9 | 1 | -0.11 |
Chronic Kidney Disease | 0.5 | 0.4 | 0.25 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.4 | -1 |
Chronic Urticaria (Hives) | 0.8 | 0.8 | |
Coagulation / Micro clot triggering bacteria | 0.9 | 0.2 | 3.5 |
Colorectal Cancer | 1.3 | 0 | 0 |
Constipation | 0.7 | 0.7 | |
Coronary artery disease | 0.2 | 0.2 | 0 |
COVID-19 | 1.8 | 1.7 | 0.06 |
Crohn's Disease | 1.9 | 1.8 | 0.06 |
cystic fibrosis | 0.7 | 0.1 | 6 |
deep vein thrombosis | 0.7 | 0.2 | 2.5 |
Depression | 2 | 1.3 | 0.54 |
Dermatomyositis | 0 | 0 | |
Eczema | 0.4 | 0 | 0 |
Endometriosis | 1 | 0.8 | 0.25 |
Eosinophilic Esophagitis | 0.1 | 0.2 | -1 |
Epilepsy | 0.4 | 0.6 | -0.5 |
Fibromyalgia | 0.5 | 0.1 | 4 |
Functional constipation / chronic idiopathic constipation | 1.7 | 0.1 | 16 |
gallstone disease (gsd) | 0.8 | 0.1 | 7 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | |
Generalized anxiety disorder | 0.7 | 0.1 | 6 |
Graves' disease | 0.3 | 0.3 | |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 0.1 | 0.5 | -4 |
Hidradenitis Suppurativa | 0.5 | 0.2 | 1.5 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1 | 1 | |
hyperglycemia | 0.2 | 0.3 | -0.5 |
Hyperlipidemia (High Blood Fats) | 0 | 0 | |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 0.7 | 0.5 | 0.4 |
Hypothyroidism | 0 | 0 | |
Hypoxia | 0.3 | 0.3 | |
IgA nephropathy (IgAN) | 0.9 | -0.9 | |
Inflammatory Bowel Disease | 0.8 | 1.6 | -1 |
Insomnia | 0.1 | 0.5 | -4 |
Intracranial aneurysms | 0.5 | 0.5 | |
Irritable Bowel Syndrome | 1.1 | 0.9 | 0.22 |
Liver Cirrhosis | 1.3 | 0.9 | 0.44 |
Long COVID | 1.2 | 2.6 | -1.17 |
Low bone mineral density | 0.4 | -0.4 | |
Lung Cancer | 0.2 | 0.2 | 0 |
ME/CFS with IBS | 0.1 | 0.1 | 0 |
ME/CFS without IBS | 0.1 | 0.5 | -4 |
Menopause | 0.1 | 0.1 | |
Metabolic Syndrome | 1.6 | 1 | 0.6 |
Mood Disorders | 3 | 1.3 | 1.31 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 0.9 | 1.7 | -0.89 |
Multiple system atrophy (MSA) | 0.2 | -0.2 | |
Neuropathy (all types) | 0.2 | -0.2 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | 0.7 | -2.5 |
NonCeliac Gluten Sensitivity | 0 | 0 | |
Obesity | 1.1 | 0.7 | 0.57 |
obsessive-compulsive disorder | 2 | 0.1 | 19 |
Osteoarthritis | 0.3 | 0.2 | 0.5 |
Osteoporosis | 0.7 | 0.1 | 6 |
Parkinson's Disease | 1.1 | 1.1 | 0 |
Polycystic ovary syndrome | 0.7 | 0.5 | 0.4 |
Postural orthostatic tachycardia syndrome | 0 | 0 | |
Premenstrual dysphoric disorder | 0 | 0.2 | 0 |
Psoriasis | 0.8 | 0.7 | 0.14 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.7 | 0.3 | 4.67 |
Rosacea | 0.2 | 0.2 | |
Schizophrenia | 1.6 | 0.2 | 7 |
scoliosis | 1.4 | -1.4 | |
Sjögren syndrome | 0.9 | 0.3 | 2 |
Sleep Apnea | 0.3 | 0.1 | 2 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0 | 0 |
Stress / posttraumatic stress disorder | 0.8 | 0.1 | 7 |
Systemic Lupus Erythematosus | 1.1 | 0.6 | 0.83 |
Tic Disorder | 0.2 | 0 | 0 |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 1.2 | 0.4 | 2 |
Type 2 Diabetes | 1.6 | 1 | 0.6 |
Ulcerative colitis | 0.8 | 0.8 | 0 |
Unhealthy Ageing | 0.9 | 0 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.